Exploratory clinical trials inhibiting MMP-9, factors expressed mainly by neutrophils, have gained some promising results, demonstrating reduced alteration of BBB and neural tissue damage, both processes important in MS and stroke pathology [201]. This evidence concerns the gene MMP9 and myeloid sarcoma.